Statins for the primary prevention of cardiovascular disease
71 results
1 - 71
Statins for the primary prevention of cardiovascular disease
Statins for the primary prevention of cardiovascular disease 
USPSTF 2022: updated review of statins for the primary prevention of cardiovascular disease- Treatment of dyslipidaemias
- Statins best for cardiovascular and all-cause mortality prevention overall and for primary prevention (PEER umbrella review)
- USPSTF 2016 recommendations on statin use for primary prevention of CVD
- Statins ineffective for primary prevention in patients 75 years or older without diabetes
- Smaller benefit of statins without heart disease
- Statins for hyperlipidemia reduce all-cause mortality
- Comprehensive treatment and follow-up of type 2 diabetes
- Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease
- Statins of modest benefit for low- to moderate-risk persons (NNT ~ 80)
- Ezetimibe for the prevention of cardiovascular disease
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- Fibrates for primary prevention of cardiovascular disease events
- More nuanced guidelines for lipid lowering to prevent CV disease
- Statins effective for LDL 190 mg/dL or higher, regardless of risk level
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
- HMG CoA reductase inhibitors (statins) for kidney transplant recipients
- PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
- Statins for primary prevention of venous thromboembolism
- Niacin for primary and secondary prevention of cardiovascular events: Cochrane systematic review
- Fibrates for primary prevention of cardiovascular disease
- Systematic reviews support colchicine for secondary prevention of atherosclerotic cardiovascular disease
- Statins for primary prevention of venous thromboembolism: Cochrane systematic review
- Lipid treatment for primary prevention not effective in older adults
- PCSK9 inhibitors for prevention of cardiovascular disease
- Statins for the primary prevention of venous thromboembolism
- Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia
- Statin therapy decreases cardiac events
- AHA/ACC guideline for the primary prevention of stroke
- Preoperative statin therapy for adults undergoing cardiac surgery
- Low-dose aspirin for prevention of vascular events in type 2 diabetes
- Peri-op fluvastatin reduces myocardial ischemia after vascular surgery
- Hypertension: investigations, treatment initiation and non-pharmacological treatment
- Small reduction in CV outcome after ischemic stroke with lower LDL target, but also harms; no change in all-cause mortality
- Icosapent ethyl reduces risk of CV death in patients with CV disease, low LDL, and high triglycerides (REDUCE-IT)
- Fibrates for secondary prevention of cardiovascular disease and stroke
- Efficacy and safety of cholesterol lowering by statins
- Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease
- In very-high-risk patients with vascular disease, evolocumab slightly reduces nonfatal MI but not mortality (FOURIER)
- Adding coronary computed tomographic angiogram to chest pain assessment reduces likelihood of nonfatal myocardial infarction over 10 years (SCOT-HEART)
- Mobile phone‐based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults
- Interventions to improve adherence to lipid‐lowering medication
- Niacin not effective in CAD with low HDL cholesterol (AIM-HIGH)
- Dietary advice for reducing cardiovascular risk
- Preoperative coronary interventions for preventing acute myocardial infarction in the perioperative period of major open vascular or endovascular surgery